Primary Care Intervention for PTSD in Ethiopia

Sponsor
University of California, Los Angeles (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT04385498
Collaborator
Addis Ababa University (Other)
45
Enrollment
1
Location
2
Arms
23
Anticipated Duration (Months)
2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Mixed methods (qualitative and quantitative) randomized pilot feasibility trial (n=40) to refine the the Brief Relaxation, Education and Trauma Healing (BREATHE) Ethiopia intervention and explore effectiveness and implementation. Fifty patients will be enrolled across the pre-pilot and the pilot to account for potential treatment dropout.

  1. Primary outcomes: Change in hypothesized treatment mechanisms: (1) increased knowledge about PTSD; reductions in (2) PTSD-related stigma; (3) trauma-related cognitions; and (4) self-reported arousal; (5) increased use of stress management strategies; and (6) reductions in physiological arousal as measured by increased heart rate variability.

  2. Secondary outcomes: Change in symptoms and functional impairment. Reductions in (1) PTSD (2) depression and anxiety symptoms, and (3) functional impairment.

  3. Process evaluation: Mixed methods multi-stakeholder process evaluation of the implementation of the intervention as measured by the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, Maintenance). We will collect qualitative data on Adoption and Implementation (e.g. facilitators and barriers to intervention delivery) and quantitative assessment of patient and provider participation and retention (Reach), satisfaction (Adoption) and fidelity (Implementation).

Condition or DiseaseIntervention/TreatmentPhase
  • Behavioral: BREATHE Intervention
  • Behavioral: Treatment as Usual
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
45 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Posttraumatic Stress Disorder Intervention for People With Severe Mental Illness in Low- and Middle-Income Country Primary Care Settings
Actual Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

ArmIntervention/Treatment
Experimental: BREATHE Intervention

Five session program, with additional sessions provided based on the individual's learning style and needs. Sessions are designed to be 20 to 30 minutes long, to accommodate the needs of the primary health care centers. Sessions will ideally be conducted once per week, but may be conducted as infrequently as once per month.

Behavioral: BREATHE Intervention
5 session program focusing on breathing retraining, psychoeducation, and positive coping.
Other Names:
  • BREATHE Ethiopia
  • Active Comparator: Treatment as Usual

    Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm.

    Behavioral: Treatment as Usual
    Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm.

    Outcome Measures

    Primary Outcome Measures

    1. Change in PTSD Knowledge [Day 0 baseline, 3 months]

      Changes in levels of PTSD Knowledge measured by the PTSD Knowledge Test (0-14, higher scores indicating more PTSD knowledge).

    2. Change in PTSD Related Stigma [Day 0 baseline, 3 months]

      Changes in levels of PTSD Related Stigma measured by The Internalized Stigma of Mental Illness Scale (1 minimal stigma to 4 severe internalized stigma).

    3. Change in Trauma-related cognitions [Day 0 baseline, 3 months]

      Changes in levels of trauma-related cognitions assessed by the Post-Traumatic Cognitions Inventory (36-252 higher scores indicating higher incidence of negative trauma related cognitions).

    4. Change in Self-reported arousal [Day 0 baseline, 3 months]

      Changes in self-reported arousal levels measured with Self-Assessment Manikin (Self-Assessment Manikin measures arousal using 3 subscales: Valence, 1 unpleasant to 5 pleasant; Arousal rating, 1 calm to 5 excited; and Dominance, 1 independent to 5 dependent).

    5. Change in Stress management strategy use [Day 0 baseline, 3 months]

      Changes in use of the breathing retraining techniques as measured by self- and caregiver-reports during in-session homework review.

    6. Change in Physiological arousal [Day 0 baseline, 3 months]

      Changes in physiological arousal levels measured by heart rate variability (HRV).

    Secondary Outcome Measures

    1. Change in PTSD Symptoms [Day 0 baseline, 3 months]

      Changes in PTSD symptoms measured by the PTSD Checklist for Diagnostic Statistical Manual-5 (DSM-5; 0-80 higher scores indicating more severe symptoms).

    2. Change in Depression Symptoms [Day 0 baseline, 3 months]

      Changes in depression symptoms measured by the Patient Health Questionnaire (PHQ-9; 0-27 with higher scores indicating more severe depression).

    3. Change in Anxiety Symptoms [Day 0 baseline, 3 months]

      Changes in anxiety symptoms measured by the Generalized Anxiety Disorder-7 (GAD-7; 0-21 with higher scores indicating more severe anxiety).

    4. Change in Functional impairment [Day 0 baseline, 3 months]

      Changes in functional impairment assessed by the WHO Disability Assessment Schedule II (WHODAS 2.0; 0-48 with high scores indicating more severe functional impairment).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. For all participants: Being 18 years of age or older

    2. For all participants: Being able and willing to provide informed consent to participate in the study

    3. For all participants: Being able to complete procedures in Amharic or English.

    4. For patients: Treatment at a Sodo district primary care clinic for Severe Mental Illness (SMI)

    5. For patients: Identified as having:

    6. Experienced a traumatic event,

    7. Associated PTSD symptoms defined as scores on the PTSD Checklist DSM-5 (PCL-5), AND

    8. any associated functional impairment on the WHODAS-2.

    9. For health care providers: Providers working at the target health centers who administer, provider care for, or supervise the care of patients with mental health concerns.

    10. For caregivers: Being identified by the patient as a close family member or friend whom the patient gives permission to be involved in the study

    Exclusion Criteria:
    1. Current high risk of suicide as measured by the Composite International Diagnostic Interview (CIDI) Suicide module

    2. Inability to participate in the treatment, as determined by the psychiatric nurse.

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Addis Ababa UniversityAddis AbabaEthiopia

    Sponsors and Collaborators

    • University of California, Los Angeles
    • Addis Ababa University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Lauren Ng, PhD, Principal Investigator, University of California, Los Angeles
    ClinicalTrials.gov Identifier:
    NCT04385498
    Other Study ID Numbers:
    • 19-001993
    First Posted:
    May 13, 2020
    Last Update Posted:
    Mar 14, 2022
    Last Verified:
    Feb 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Lauren Ng, PhD, Principal Investigator, University of California, Los Angeles

    Study Results

    No Results Posted as of Mar 14, 2022